# States seek final approval of $29.6M Glenmark generic-drug price-fixing settlement

Attorney advertising. Brief by Lou Schwartz, Schwartz & Associates, PC, Atlanta, Georgia. Published 2026-10-30; updated 2026-10-30. Responsible attorney: Lou Schwartz. Canonical: https://www.snalawyers.com/insights/states-seek-final-approval-of-29-6m-glenmark-generic-drug-price-fixing

A coalition of 48 states and territories asked a Connecticut federal judge on October 30, 2026 to grant final approval to a $29.6 million settlement with Glenmark Pharmaceuticals resolving allegations that it conspired with competitors to inflate prices and allocate markets for generic prescription drugs. The settlement, which received preliminary approval in August 2026, would pay restitution to the states and eligible consumers and requires Glenmark to cooperate in the states' ongoing case against dozens of other corporate and individual defendants. The underlying multistate antitrust litigation, led by the Connecticut Attorney General's office, has been pending since 2016 and is nearing its first trial.

**Why it matters.** Final approval would add another sizable recovery to the long-running generic-drug price-fixing litigation, offering a benchmark for consumers and payers evaluating claims against remaining defendants.

## Sources

1. [Law360](https://www.law360.com/compliance/articles/2544498)

To ask the firm about this, use the intake assistant at https://www.snalawyers.com/insights/states-seek-final-approval-of-29-6m-glenmark-generic-drug-price-fixing#ask. General information, not legal advice.
